Makielski Jonathan C, Valdivia Carmen R
Department of Medicine, Cardiovascular Medicine Section, University of Wisconsin, Madison, WI 53705, USA.
Br J Pharmacol. 2006 May;148(1):4-6. doi: 10.1038/sj.bjp.0706713.
Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.
雷诺嗪是一种新型抗心绞痛药物，于2006年1月在美国获批用于临床。发表在同一期《英国药理学期刊》上的一项研究描述了雷诺嗪对由长QT综合征3型突变引起的晚钠电流的阻滞作用。本述评讨论了该研究的意义以及心脏晚钠电流阻滞的总体背景和意义。
